In patients with stage III EGFR-mutated NSCLC, the role of consolidation durvalumab after chemoradiation is unclear, with some preliminary data suggesting the possible lack of benefit and higher frequency of adverse events [65]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.